Afatinib Completed Phase 1 Trials for Neoplasms Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02171676BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
NCT00998296Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
NCT00809133Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
NCT02020577Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
NCT02171637Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
NCT00730821Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
NCT00716417Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
NCT02171702Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
NCT01214616BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
NCT01169675BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
NCT02171650BIBW 2992 in Patients With Advanced Solid Tumors
NCT02171663Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors
NCT02171741Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors
NCT02171728Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors